Repositioning generic drugs: Empirical Findings & Policy Implications

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

  • Johnathon Liddicoat
  • Kathleen Liddell
  • Jonathan Darrow
  • Mateo Aboy
  • Matthew Jordan
  • Minssen, Timo
Commentators claim that drug repositioning (ie developing new uses for authorised drugs) significantly slows when generics are authorised and, therefore, law reform is necessary to encourage more R&D. This study empirically examines this claim by analysing records of clinical trials. It finds that once generics are authorised: i) commercial trials continue at ‘active’ rates for approximately half of the drugs studied, and ii) the number of hospital and university trials actually increases. These findings cast doubt on whether additional incentives are needed. They also indicate that a more effective way to reposition drugs is for recently established government programmes to embrace IP strategies and leverage the hospital and university trials as an R&D pipeline.

Keywords: drug repositioning, patent law, regulatory protection, clinical trials, empirical study, generic drugs.
TidsskriftIIC International Review of Intellectual Property and Competition Law
Sider (fra-til)1287-1322
Antal sider36
StatusUdgivet - 2022

ID: 306454713